GlassScriptPhysician profile
Jennifer S Gregory
NPI 1710008784
$3,679.56
in general payments reported to CMS, 2019-2025
30 companies · $545 in 2025
The $545 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $142 · 2021: $693 · 2022: $593 · 2023: $768 · 2024: $630 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,831 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,831.15 |
| Education | $112.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $465.93 | 2023-2025 | Myfembree |
| Abbvie INC. | $422.72 | 2019-2024 | |
| Astellas Pharma US INC | $310.12 | 2023-2025 | Veozah |
| Aspira Women'S Health INC | $278.03 | 2021-2022 | |
| Pfizer INC. | $230.51 | 2020-2023 | |
| Myovant Sciences INC. | $193.65 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $185.45 | 2022-2025 | |
| Hologic Sales and Service, LLC | $150.76 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Shield Therapeutics INC | $139.02 | 2023-2024 | Accrufer |
| Exeltis, USA INC. | $129.05 | 2020-2024 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $128.62 | 2019-2024 | |
| Minerva Surgical, INC | $128.54 | 2021-2024 | |
| Biogen, INC. | $117.63 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $113.09 | 2021-2024 | Gardasil 9, Gardasil |
| Organon LLC | $110.94 | 2021-2025 | Nexplanon |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $101.16 | 2019 | |
| Avion Pharmaceuticals | $78.64 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $53.72 | 2020-2021 | |
| Evofem Biosciences, INC. | $51.80 | 2022 | |
| Agile Therapeutics, INC. | $46.98 | 2021-2022 | |
| Therapeuticsmd, INC. | $41.78 | 2019-2021 | |
| Becton, Dickinson and Company | $41.06 | 2019 | |
| Coopersurgical, INC. | $35.46 | 2022-2024 | Summit Doppler |
| Millicent US INC | $33.22 | 2024 | Femring, Intrarosa |
| Biohaven Pharmaceutical Holding Company LTD. | $26.73 | 2022 | |
| Smith+Nephew, INC. | $17.64 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.48 | 2019 | |
| Allergan, INC. | $13.23 | 2020 | |
| Duchesnay USA Incorporated | $12.21 | 2019 | |
| Kinex Medical Company LLC | $4.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.